Study Completed

Pregnancy

Bayer Identifier:

17714

ClinicalTrials.gov Identifier:

NCT02414919

EudraCT Number:

Not Available

EU CT Number:

Not Available

Duration of use of highly effective reversible contraception

Trial purpose

To assess the proportion of women who use HERC for ≥2 years of duration

Key Participants Requirements

Sex

Female

Age

15 - 44 Years

Inclusion Criteria
-Women who had an IUD or contraceptive implant inserted and removed within the University of Utah from January 1, 2004 to October 31, 2012
Exclusion Criteria

Trial summary

Enrollment Goal

13880

Trial Dates

April 2015 - March 2016

Phase

N/A

Could I Receive a placebo

Products

Mirena (Levonorgestrel IUS, BAY86-5028)

Accepts Healthy Volunteer

Where to participate

Status	Institution	Location
Completed		Salt Lake, United States

Primary Outcome

Proportion of women who use HERC
Time Frame:
2 years post-HERC initiation
Safety Issue:
No

Secondary Outcome

Duration of real world use of three different HERC devices
Time Frame:
2 years post-HERC initiation

Trial design

Real-world duration of use for highly effective reversible contraception (HERC): A retrospective review

Trial Type

Observational

Intervention Type

Drug

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.